Bayer's 51% Rally Faces a February Reckoning as Analyst Bets Diverge
Published on 11/19/2026 at 04:31 | Editorial boerse-global.deBayer shareholders have watched the stock climb 51% since the start of the year. That kind of run tends to shift the question from "is the business improving?" to "how much improvement is already priced in?" Two fresh assessments of the German group's pharmaceutical arm — and one long-range financing idea — frame the debate ahead of the company's fourth-quarter 2026 results, expected on 24 February 2027.
Berenberg's Sebastian Bray sees the pharma division generating EUR 5 billion in EBITDA for 2027, comfortably above the EUR 4.8 billion consensus. That gap is the heart of the bullish case: the brokerage is betting the market is underestimating the business. Bray points to Nubeqa and Kerendia as the growth engines that could underwrite the higher figure.
Yet Berenberg kept its rating at "Hold" even as it lifted its price target. The combination is telling. A brighter earnings outlook and a cautious recommendation are not contradictory — the business can improve while the share price has already banked much of the gain.
Two Houses, One Direction, Different Conclusions
UBS offers a more constructive read. On 4 November, analyst Matthew Weston reaffirmed a "Buy" and raised his target to EUR 66, citing strong quarterly results and, in particular, the continued momentum of the pharma division. Both brokerages share a positive operational reference point; they part ways on whether to chase the stock.
Should investors sell immediately? Or is it worth buying Bayer?
The distinction matters for anyone weighing entry at current levels. An analyst estimate is neither a company target nor realized profit. What counts is how durable the assumptions behind the projected growth turn out to be.
The Numbers Behind the Optimism
Bayer's third quarter of 2026 showed a loss per share of EUR 0.69, an improvement on the EUR 0.98 deficit in the same period a year earlier — better, but still negative. Revenue reached EUR 10.05 billion, up 4.07% from EUR 9.66 billion a year prior. Analysts expect full-year 2026 earnings of EUR 4.56 per share.
Those figures support the picture of an operational recovery without settling the larger question. A narrower loss is not the same as a sustainable turnaround, and revenue growth alone does not prove that additional business flows through to the bottom line. Nor can the group's per-share loss be read directly against Berenberg's divisional EBITDA estimate — the two measure different things, and treating the optimistic segment forecast as proof of company-wide earnings security would be a stretch.
Sunharbo Adds a Second Front
Beyond the two named growth drivers, Bayer has a concrete pipeline catalyst in Sunharbo, whose active ingredient asundexian has already won US approval. The drug is cleared as an add-on to platelet inhibitors for certain adults after an ischemic stroke or high-risk TIA; it is not intended for atrial fibrillation.
The OCEANIC-STROKE trial enrolled 12,327 adults. Recurrent ischemic strokes occurred in 6.2% of patients on asundexian versus 8.4% on placebo. Serious bleeding was not elevated overall, though the data hinted at a higher bleeding risk in people over 75 and during the first 90 days. A European approval decision is still pending.
Medical benefit lays a foundation for commercial prospects but does not substitute for proof of them. What the drug actually contributes to revenue remains to be demonstrated.
A Listing Idea, Not a Plan
Bray also floats the possibility that Bayer could list Monsanto on the stock exchange before the end of the decade, using the proceeds to fund pharmaceutical development. That is the analyst's financing scenario — not an announced corporate plan — and it carries no confirmed execution date. Investors who weight it heavily must accept the uncertainty over both timing and delivery.
Bayer at a turning point? This analysis reveals what investors need to know now.
The cautious reading starts with separating these threads. An approval does not guarantee a specific revenue contribution, and a strategic option is not a decision. Anyone treating either as a locked-in future earnings stream would be running ahead of several unresolved steps.
What February Must Deliver
The next hard checkpoint is the fourth-quarter 2026 report on 24 February 2027. The key question is whether Bayer can back the earnings expectations that have built up — specifically, whether Nubeqa and Kerendia can operationally underpin the more optimistic divisional view.
If they do, the rally has a fundamental leg to stand on and further estimate revisions could follow. If growth merely meets the existing consensus, Berenberg's extra optimism stays unearned. And if expectations for those drugs' contribution slip, the case for a higher valuation loses its anchor.
After a year like this one, even a solid performance may not be enough to generate fresh upside. The measure for investors is not whether the share price recovery repeats itself, but whether the expected earnings improvement becomes more credible. On that score, the February numbers will speak louder than any long-range financing option.
Ad
Bayer Stock: New Analysis - 19 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
